Roche Holdings Ltd.
(
RHHBY
) recently announced its intension to present results from thirteen
studies conducted with pipeline candidates as well as approved
products at the upcoming European Society for Medical Oncology
(ESMO) Congress.
Roche will be presenting additional data, including overall
survival (OS) data, from its phase III EMILIA study. The study
compared trastuzumab emtansine (T-DM1) to Xeloda along with
lapatinib in HER2-positive unresectable locally advanced or
metastatic breast cancer patients who were previously treated with
Herceptin and taxane chemotherapy. We note that the study met both
the co-primary endpoints of longer progression free survival (PFS)
and OS.
The company will also present data from the phase III HERA
(HERceptin Adjuvant) study. The study evaluated Herceptin's impact
on disease free survival in women suffering from HER2-positive
early breast cancer after completing standard chemotherapy.
Apart from HER2-positive breast cancer treatments, Roche is
looking to present data on skin cancer candidates. Data
presentation will include results from a pilot study conducted with
24 patients suffering from BRAF V600 mutation-positive metastatic
melanoma and symptomatic brain metastases treated with Zelboraf. We
note that Zelboraf is already approved in the US and Switzerland to
treat patients suffering from inoperable or metastatic
melanoma.
Earlier this moth, Roche provided an update on its research and
development (R&D) programs and its strategy on innovation for
unmet medical needs. The company is expected to present results
from 19 late-stage clinical trials in the next 18 months.
Of these, 12 studies are investigating new molecular entities
(NMEs). Moreover, Roche expects three additional NMEs to reach the
Lifecycle Investment Point (LIP) and move to late-stage development
by year end. Roche allotted half of its R&D budget to its
oncology segment.
Moreover, Roche implemented rigorous portfolio prioritisation,
new development designs, and cost-saving initiatives to keep its
R&D budget stable despite its significant pipeline
progress.
Our Recommendation
Roche, headquartered in Basel, Switzerland, carries a Zacks #3
Rank (Hold rating) in the short run.
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment
Research